CMPS (Compass Pathways) stock will retrace below $12.00 within 15 trading days of its most recent 8%+ single-day spike, absent a confirmed Phase 3 data readout or major partnership announcement.

When a small biotech stock jumps 8% or more in one day without real news, retail traders are usually driving the move. Big institutional investors use these jumps as a chance to sell and get out. Without actual drug approval or a partnership announcement, the stock typically falls back down within 2–3 weeks. This prediction tracks one specific stock spike.

Single-day moves of 8%+ on no confirmed hard catalyst are characteristic of momentum-driven retail trading. Institutional holders with cost bases well above current levels use such spikes as exit liquidity. Without a durable fundamental catalyst (Phase 3 efficacy data or a pharma partnership with disclosed terms), mean reversion within 15 trading days is the historical base rate for small-cap biotech momentum pops. Resolve date set to June 20, 2026 — 15 trading days from prediction date.